HT
NBIX icon

Headlands Technologies’s Neurocrine Biosciences NBIX Stock Holding History

Headlands Technologies’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,852
Closed -$861K – 1045
2025
Q2 		$861K Buy
6,852
+4,930
+257% +$565K 0.1% 209
2025
Q1 		$213K Sell
1,922
-3,915
-67% -$496K 0.02% 446
2024
Q4 		$797K Sell
5,837
-13,566
-70% -$1.68M 0.08% 250
2024
Q3 		$2.24M Buy
19,403
+10,340
+114% +$1.42M 0.26% 87
2024
Q2 		$1.25M Buy
9,063
+8,865
+4,477% +$1.22M 0.13% 142
2024
Q1 		$27.3K Sell
198
-1,356
-87% -$185K 0.01% 848
2023
Q4 		$205K Sell
1,554
-8,799
-85% -$1.01M 0.06% 271
2023
Q3 		$1.16M Buy
10,353
+2,762
+36% +$291K 0.57% 41
2023
Q2 		$716K Buy
+7,591
New +$742K 0.23% 107

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Headlands Technologies's NBIX Position: Q3 2025 in Review

Headlands Technologies sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 6,852 shares — an estimated $861K sold.

Headlands Technologies first reported a position in NBIX in Q2 2023 and held it in 9 quarters. The position peaked at $2.24M in Q3 2024. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Headlands Technologies reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Headlands Technologies sold 6,852 Neurocrine Biosciences shares in Q3 2025, an estimated $861K.
  • Headlands Technologies first reported a position in Neurocrine Biosciences in Q2 2023 and held it in 9 quarters.
  • Headlands Technologies's Neurocrine Biosciences position peaked at $2.24M in Q3 2024.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Headlands Technologies's 13F filing for Q3 2025, filed 12 Nov 2025.